‘I’m his lawyer’ — acting Attorney General briefly forgets he’s supposed to represent Americans

At a Senate confirmation hearing, Acting Attorney General Todd Blanche said the $1.776B “Anti-Weaponization Fund” is “not moving forward,” but Republicans pressed him over whether Trump has committed in writing to kill the fund. The hearing also revived scrutiny of DOJ actions tied to Trump’s tax settlement (including an audit-immunity component) and the staggered release of Jeffrey Epstein records, where Blanche acknowledged redaction mistakes affected about 1% of documents. Overall tone was cautious for Blanche’s confirmation prospects, with Cornyn saying he has “some concerns” and no guarantee the fund can’t be resurrected.

Analysis

This is primarily a governance and headline-risk event for Trump-linked equity, not a direct operating catalyst. For DJT, the important mechanism is that every sign of institutional conflict around the administration’s legal machinery keeps a political-risk premium embedded in the stock, but the incremental impact is usually short-lived unless it changes the probability of a broader legal or regulatory outcome. In practice, the market will trade the appearance of control and credibility more than the underlying legal merits.

The second-order effect is that a more politically aligned DOJ can help Trump-adjacent names on the margin in the next 1-3 months by reducing fear of aggressive federal action, but that benefit is fragile because courts, state AGs, and congressional oversight remain independent constraints. If Senate resistance hardens or the confirmation path weakens, DJT likely underperforms on sentiment alone; if Blanche clears, the relief rally may be brief because the overhang shifts from personnel to process and potential judicial reversals.

Contrarian takeaway: the consensus may be overestimating the durability of any “protective” DOJ effect on Trump assets. The bigger risk is not one more hearing, but the accumulation of credibility damage that widens the gap between narrative-driven price action and fundamentals, which tends to compress violently once the next adverse ruling or investigation headline hits. PUPOF has no clear standalone catalyst here; without a direct legal or cash-flow linkage, it remains a watch item rather than a trade.

Key Decisions for Investors

• Short DJT on any post-hearing bounce into confirmation speculation; use a 2-6 week horizon and keep size modest because the name can trade on emotion rather than fundamentals. Falsify the short if the committee vote locks in unanimous GOP support and the stock holds gains for several sessions.
• If implied volatility is not already extreme, buy DJT 1-2 month put spreads on strength rather than at the lows. This gives defined risk into the next Senate/process catalyst while limiting decay if the story fades quickly.
• Set an alert on committee vote count and any written DOJ statement about the fund/settlement language; that is the real catalyst, not the hearing optics. A formal written commitment would reduce headline risk and likely force cover in DJT.
• Avoid trading PUPOF off this headline absent evidence of direct exposure; treat it as a no-trade until a legal or financing linkage is identified. Missing data: whether the fund/settlement mechanics create any balance-sheet, litigation reserve, or governance impact for the company.